Home LiteratureArticle Details
PMID: 23165303 Published · ppublish English Journal Article Review

Resistant hypertension--its identification and epidemiology.

Nature reviews. Nephrology ·Vol. 9 ·No. 1 ·2013-01-00 ·Pages 51-8

Sarafidis PA, Georgianos P, Bakris GL

Abstract

Resistant hypertension is currently defined as the failure to achieve a goal blood pressure <140/90 mmHg in patients who are compliant with maximal tolerated doses of a minimum of three antihypertensive drugs, one of which must be a diuretic. The increasing prevalence of obesity and hypertension in the general population mean that this disorder has gained attention in the past decade. In the past 2 years, large-scale population-based studies such as the US National Health and Nutrition Examination Survey (NHANES) have specifically examined the prevalence and incidence of resistant hypertension, and associated risk factors. The findings suggest the prevalence of resistant hypertension is 8-12% of adult patients with hypertension (6-9 million people). The increasing prevalence of resistant hypertension contrasts with the improvement in blood pressure control rates during the same period. Studies also show that patients with resistant hypertension aged >55 years, of black ethnicity, with high BMI, diabetes or chronic kidney disease have an increased risk of cardiovascular events compared to nonresistant hypertensive patients. Analyses that exclude the effects of white-coat hypertension and pseudoresistant hypertension are also needed to clarify the epidemiology of true resistant hypertension.

MeSH Terms
Coronary Vasospasm/diagnosis,epidemiology Humans Hypertension/diagnosis,epidemiology Incidence Prevalence Prognosis
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Sarafidis Pantelis A
Section of Nephrology and Hypertension, 1st Department of Medicine, American Hellenic Educational Progressive Association (AHEPA), University General Hospital, Aristotle University of Thessaloniki, St Kiriakidis 1, PO 54636, Thessaloniki, Greece.
Georgianos Panagiotis
Bakris George L
Supplementary Concepts
Hypertension Resistant to Conventional Therapy (Disease)
References (47)
47 references, click to expand
  1. Predictors of new-onset kidney disease in a community-based population.
    JAMA. 2004 Feb 18;291(7):844-50 PMID: 14970063
  2. Is resistant hypertension really resistant?
    Am J Hypertens. 2001 Dec;14(12):1263-9 PMID: 11775136
  3. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.
    Clin Ther. 2009 May;31(5):1116-23 PMID: 19539112
  4. Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.
    Hypertension. 2000 Oct;36(4):594-9 PMID: 11040241
  5. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
    Hypertension. 2008 Jun;51(6):1403-19 PMID: 18391085
  6. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.
    JAMA. 2010 May 26;303(20):2043-50 PMID: 20501926
  7. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.
    Circulation. 2011 Aug 30;124(9):1046-58 PMID: 21824920
  8. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
    J Hypertens. 2011 Oct;29(10):2004-13 PMID: 21881528
  9. Resistant hypertension in a tertiary care clinic.
    Arch Intern Med. 1991 Sep;151(9):1786-92 PMID: 1888244
  10. Burden of resistant hypertension in hypertensive patients with non-dialysis chronic kidney disease.
    Kidney Blood Press Res. 2011;34(1):58-67 PMID: 21212686
  11. Heart disease and stroke statistics--2011 update: a report from the American Heart Association.
    Circulation. 2011 Feb 1;123(4):e18-e209 PMID: 21160056
  12. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.
    J Hypertens. 2007 Sep;25(9):1751-62 PMID: 17762635
  13. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
    N Engl J Med. 2008 Dec 4;359(23):2417-28 PMID: 19052124
  14. Clinical practice. Resistant or difficult-to-control hypertension.
    N Engl J Med. 2006 Jul 27;355(4):385-92 PMID: 16870917
  15. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
    Clin Cardiol. 2012 Sep;35(9):528-35 PMID: 22573363
  16. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.
    JAMA. 2003 May 14;289(18):2363-9 PMID: 12746359
  17. What is the prevalence of resistant hypertension in the United States?
    Curr Opin Cardiol. 2012 Jul;27(4):386-91 PMID: 22596184
  18. Hypertension treatment and control in five European countries, Canada, and the United States.
    Hypertension. 2004 Jan;43(1):10-7 PMID: 14638619
  19. Heart disease and stroke statistics--2012 update: a report from the American Heart Association.
    Circulation. 2012 Jan 3;125(1):e2-e220 PMID: 22179539
  20. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.
    Hypertension. 2007 Jan;49(1):69-75 PMID: 17159087
  21. Prognostic influence of office and ambulatory blood pressures in resistant hypertension.
    Arch Intern Med. 2008 Nov 24;168(21):2340-6 PMID: 19029499
  22. Prognostic value of nocturnal blood pressure reduction in resistant hypertension.
    Arch Intern Med. 2009 May 11;169(9):874-80 PMID: 19433699
  23. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.
    J Hypertens. 2012 Jun;30(6):1211-6 PMID: 22525201
  24. Incidence and prognosis of resistant hypertension in hypertensive patients.
    Circulation. 2012 Apr 3;125(13):1635-42 PMID: 22379110
  25. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
    Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290 PMID: 15114537
  26. Resistant hypertension.
    J Hypertens. 2005 Aug;23(8):1441-4 PMID: 16003165
  27. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension.
    J Hypertens. 2001 Nov;19(11):2063-70 PMID: 11677373
  28. The burden of blood pressure-related disease: a neglected priority for global health.
    Hypertension. 2007 Dec;50(6):991-7 PMID: 17954719
  29. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Lancet. 2002 Mar 23;359(9311):995-1003 PMID: 11937178
  30. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.
    JAMA. 2003 Jul 9;290(2):199-206 PMID: 12851274
  31. Mechanisms and treatment of resistant hypertension.
    J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44 PMID: 18326968
  32. Blood pressure and end-stage renal disease in men.
    N Engl J Med. 1996 Jan 4;334(1):13-8 PMID: 7494564
  33. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    JAMA. 2002 Dec 18;288(23):2981-97 PMID: 12479763
  34. Refractory hypertension: definition, prevalence, and patient characteristics.
    J Clin Hypertens (Greenwich). 2012 Jan;14(1):7-12 PMID: 22235818
  35. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.
    JAMA. 2004 Jan 21;291(3):335-42 PMID: 14734596
  36. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
    Hypertension. 2003 Dec;42(6):1206-52 PMID: 14656957
  37. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
    Lancet. 2002 Dec 14;360(9349):1903-13 PMID: 12493255
  38. Epidemiology of resistant hypertension.
    J Clin Hypertens (Greenwich). 2011 Jul;13(7):523-8 PMID: 21762366
  39. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.
    Hypertension. 2011 May;57(5):898-902 PMID: 21444835
  40. Hypertension awareness, treatment, and control in chronic kidney disease.
    Am J Med. 2008 Apr;121(4):332-40 PMID: 18374693
  41. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.
    J Clin Hypertens (Greenwich). 2008 Feb;10(2):130-9 PMID: 18256578
  42. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    JAMA. 2003 Dec 3;290(21):2805-16 PMID: 14657064
  43. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
    Lancet. 1990 Apr 7;335(8693):827-38 PMID: 1969567
  44. Prevalence of resistant hypertension in the United States, 2003-2008.
    Hypertension. 2011 Jun;57(6):1076-80 PMID: 21502568
  45. Resistant hypertension revisited: a comparison of two university-based cohorts.
    Am J Hypertens. 2005 May;18(5 Pt 1):619-26 PMID: 15882544
  46. Resistant hypertension: an overview of evaluation and treatment.
    J Am Coll Cardiol. 2008 Nov 25;52(22):1749-57 PMID: 19022154
  47. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension.
    J Hypertens. 2010 Jul;28(7):1547-53 PMID: 20467326
Article Info
Journal
Nature reviews. Nephrology
Abbr.
Nat Rev Nephrol
ISSN
1759-507X
Published
2013-01-00
Epub
2012-00-20
Pages
51-8
Language
English
Region
England
NLM ID
101500081
Subset
IM
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]